'Killer' cells used to combat rare cancerSeptember 10, 2002Scientists from the University of Edinburgh are using immune cells harvested from blood donors to help fight an unusual cancer which can affect transplant patients. And their findings, published recently in The Lancet show that the therapy has proved effective in a number of cases. The treatment proved successful last year in saving the life of a four-year-old boy from Birmingham, who developed the cancer- post-transplant lympho-proliferative disease- following a liver and bowel transplant. The technique, which involves boosting the patient's own immune system to fight cancer without affecting the transplanted organ, can also be adapted to treat other virus infections, or AIDS patients who have developed lymphomas. Clinical research scientist Dr Tanzina Haque explained: "The Epstein-Barr virus (EBV) is a common virus best known for causing glandular fever, and is carried by about 90% of the population, without a problem. When a patient receives an organ transplant, he or she is given immuno-suppressive drugs to stop the body rejecting the organ, but this also lowers their immunity to infections by removing the body's 'killer' cells, the cytotoxic T-lymphocytes. If a transplant patient's immunity is compromised, EBV can infect cells called B-lymphocytes, causing them to grow in an uncontrolled way and become malignant. The resulting cancer can be fatal in up to 70% of cases." Dr Haque said that to reduce doses of immuno-suppressive drugs could cause organ transplant rejection, so the Edinburgh team, headed by Professor Dorothy Crawford and backed by funding from Cancer Research UK, devised a method of removing 'killer' cells from screened blood donations and tissue-type matching them to transplant patients. Should any patients develop lymphoma, they can be infused with matched cells from the bank containing more than 100 blood donations. The technique, known as Cytotoxic T-Lymphocyte (CTL) Therapy, has shown to have no adverse side-effects for patients. Results published in The Lancet show of eight patients in the trial who were suitable for treatment, two died, five made a complete recovery, two did not respond and one showed a partial response. Two further patients died before their tumour response could be evaluated. Dr Haque said this UK-wide multicentre clinical trial could not have been possible without the collaboration of the Scottish National Blood Transfusion Service, different transplant centers, and the many blood donors who helped by allowing their blood to be used for generating the T-cells. | |||||||||||||||||||||
|
Related Cancer Current Events and Cancer News Articles Genetic breakdown in Fanconi anemia may have link to HPV-associated cancer A genetic malfunction that causes DNA instability in people with the blood disorder Fanconi anemia may put them at high risk for squamous cell carcinomas linked to human papillomavirus (HPV), according to a study posted online ahead of print by Oncogene. International study supports new standard of treatment for women with advanced ovarian cancer Results of a phase III, international randomized clinical trial demonstrate a new standard of care for treating advanced ovarian cancer that significantly reduces side-effects and post-operative deaths compared to the previously established treatment course. Researchers identify cell group key to Lyme disease arthritis A research team led by the La Jolla Institute for Allergy & Immunology and Albany Medical College has illuminated the important role of natural killer (NK) T cells in Lyme disease, demonstrating that the once little understood white blood cells are central to clearing the bacterial infection and reducing the intensity and duration of arthritis associated with Lyme disease. Researchers Discover New Enzyme in Cancer Growth While studying the mechanics of blood clots, researchers at the University of Oklahoma Health Sciences Center discovered a new enzyme that not only affects the blood, but seems to play a primary role in how cancer tumors expand and spread throughout the body. Angled gantry technique reduced breast radiation exposure by 50 percent A novel angled gantry approach to coronary CT angiography reduced radiation exposure to the breast by more than 50%, according to Thomas Jefferson University researchers. HER2 levels may aid in treatment selection for metastatic breast cancer Findings published in the December 1, 2008, issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, show lapatinib benefits women with HER2-positive breast cancer, while women with HER2-negative breast cancer or those who express EGRF alone derive no incremental benefit. Drop in cancer deaths tied primarily to gains in behavior and screening Improvements in behavior and screening have contributed greatly to the 13 percent decline in cancer mortality since 1990, with better cancer treatments playing a supporting role, according to new research from David Cutler of Harvard University. Plants display 'molecular amnesia' Plant researchers from McGill University and the University of California, Berkeley, have announced a major breakthrough in a developmental process called epigenetics. They have demonstrated for the first time the reversal of what is called epigenetic silencing in plants. New breast imaging technology targets hard-to-detect cancers Breast-specific gamma imaging (BSGI) is effective in the detection of cancers not found on mammograms or by clinical exam, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA). Dancing atoms now understood In developing a model to explain the motion of atoms in a magnetic field, scientists have overcome a decades-old obstacle to understanding a key component of magnetic resonance. More Cancer Current Events and Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||